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A B S T R A C T
Background: Human papillomavirus (HPV) vaccine should reduce cervical dysplasia before cervical
cancer. However, dysplasia diagnosis is screening-dependent. Accurate screening estimates are needed.
Purpose: To estimate the percentage of women in a geographic population that has had cervical cancer
screening.
Methods: We analyzed claims data for (Papanicolau) Pap tests from 2008–2012 to estimate the
percentage of insured women aged 18–39 years screened. We estimated screening in uninsured women
by dividing the percentage of insured Behavioral Risk Factor Surveillance Survey respondents reporting
previous-year testing by the percentage of uninsured respondents reporting previous-year testing, and
multiplying this ratio by claims-based estimates of insured women with previous-year screening. We
calculated a simple weighted average of the two estimates to estimate overall screening percentage. We
estimated credible intervals using Monte-Carlo simulations.
Results: During 2008–2012, an annual average of 29.6% of women aged 18–39 years were screened.
Screening increased from 2008 to 2009 in all age groups. During 2009–2012, the screening percentages
decreased for all groups, but declined most in women aged 18–20 years, from 21.5% to 5.4%. Within age
groups, compared to 2009, credible intervals did not overlap during 2011 (except age group 21–29 years)
and 2012, and credible intervals in the 18–20 year group did not overlap with older groups in any year.
Conclusions: This introduces a novel method to estimate population-level cervical cancer screening.
Overall, percentage of women screened in Portland, Oregon fell following changes in screening
recommendations released in 2009 and later modified in 2012.
ã 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Cervical intraepithelial neoplasia and adenocarcinoma in situ
(CIN2+) are high grade cervical lesions caused by persistent
infection with human papillomavirus (HPV) [1]. Although asymp-
tomatic, these lesions can progress to invasive cervical cancer. CIN2
+ can be detected and treated through routine cervical cancer
screening with the Papanicolau (Pap) test which has been the basis
of cervical cancer prevention since the 1950s [2]. During 2008, in
collaboration with the Centers for Disease Control and Prevention
(CDC), five states including California, Connecticut, New York,
Tennessee, and Oregon established population-based surveillance
of CIN2+ in order to monitor the impact of HPV vaccines that target
the HPV types that cause the majority of CIN2+ and cervical cancers
[3]. However, diagnosis of CIN2+ is screening-dependent, and
directly impacted by recent changes in recommendations for older
age at first screening and longer screening intervals for all ages [4].
Therefore, accurate estimates of the percentage of women
screened are needed to determine the independent impact of
HPV vaccination on reducing the burden of CIN2+.
Determining the actual number of women screened in the
United States is challenging. New Mexico has the only existing
state-level cervical cancer screening registry, established in 2006
[4]. Collecting cervical cancer screening information from labs
would be resource intensive and add substantial reporting burden
for laboratories. Women may have multiple Pap tests in one year
from the same or different providers leading to overestimation of
cervical cancer screening percentages, if data are not de-
duplicated.
Historically, estimates of cervical cancer screening percentages
in the U.S. have been obtained from national surveys such as the
National Health Interview Survey (NHIS) and the Behavioral Risk
Factor Surveillance System (BRFSS) survey [5,6]. These data are
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self-reported and are subject to reporting bias, leading to
overestimation of cervical cancer screening percentages [7]. In
addition, surveys produce national and state-level estimates, but
lack granularity to produce precise estimates for smaller areas.
Non-telephone-equipped households, cell phone-only house-
holds, and increased non-response percentages have also become
a growing challenge for telephone surveys [8].
Administrative health care claims data represent an alternative
data source for estimating the percentage of insured women that
receive a Pap smear. Claims data have been used within health
plans to measure the percentage of women with recent Pap tests in
closed populations [9]. In a study published in 2004, Insinga et al.
used claims data for enrollees 10 years old insured by the Kaiser
Permanente Northwest (KPNW) health plan and estimated an
annual Pap smear percentage of 31.2 per 100 women enrolled [10].
However, claims data provide no estimates of Pap smears among
uninsured women. In the current study, we aimed to estimate
cervical screening percentages among women residing in the
Portland, Oregon metropolitan area, one of the 5 defined
geographic areas established to monitor HPV vaccine impact on
CIN2+. Specifically, we used claims data to directly estimate the
percentage of insured women living within the catchment area and
enrolled in a variety of health plans that received at least one Pap
test during a calendar year, and adjusted these estimates by the
relative frequency of Pap tests among uninsured women to derive
an indirect estimate of screening in uninsured women. Finally, we
combined these two estimates to arrive at an estimate of the
percentage of the entire population screened.
2. Methods
2.1. Study population
The Oregon Health Authority (OHA), Public Health Division,
conducts CIN2+ surveillance among women who reside in a
contiguous 28-zip-code area of the Portland metropolitan area.
Women were included in the study if they were aged 18–39 years,
resided in the catchment area, and had at least one Pap smear in a
calendar year. We categorized women into three age groups: 18–
20, 21–29, and 30–39 years. We chose these age groupings because
they coincide with the ages for which screening recommendations
vary. We cut the upper age group off at 39 years because this is the
upper age limit for inclusion in the CIN2+ surveillance project. In
2010, 119,558 women aged 18–39 years lived in the surveillance
area [11]. An estimated 79.3% of this population had health
insurance coverage, defined as individual, group, Medicare,
Medicaid, or a combination of these [12].
2.2. Data sources
We acquired county-level population data by age in 1-year
intervals from the U.S. census [11]. We used estimates of
percentages of insured and uninsured women in the catchment
area from the American Community Survey (ACS) (Table 1).
Administrative claims data for health plan enrollees were
obtained from Quality Corporation (QCorp). QCorp is a non-profit
organization that collaborates with health insurance companies,
Medicaid, and Medicare in Oregon to collect and compile
healthcare-related administrative claims data [13]. Both private
and public health care insurers use these data to track and report
on performance measures. QCorp reports that claims data are
available for approximately 85% of the insured population in the
catchment area. We used QCorp-supplied claims data for services
provided during 2008–2012 to determine whether a claim for a Pap
test had been submitted on behalf of a woman enrolled by any of
the collaborating insurers. QCorp mostly used Current Procedure
Terminology (CPT), and Health Care Procedure Coding System
(HCPCS), and on rare occasions, Hospital Revenue Code sets, and
International Classification of Diseases (ICD) codes to identify Pap
claims (see Appendix A for a list of codes). These codes are included
in the specifications for the National Committee for Quality
Assurance (NCQA) Healthcare Effectiveness Data and Information
Set (HEDIS) cervical cancer screening measure. QCorp also
provided a count of insured women by age and county of residence
whose claims would have been eligible to be captured, i.e.,
“number enrolled.”
We used survey responses to the Oregon Behavioral Risk Factor
Surveillance System (BRFSS) to determine relative frequency of
cervical screening among uninsured and insured women, but not to
directly estimate the percentage of insured or uninsured women
that had a Pap test [14]. BRFSS surveyors asked respondents if they
ever had a Pap test, and how long it had been since they had their
last Pap test. In addition, the survey included a question about
whether or not a respondent had health insurance, and asked
respondents if they had any kind of health care coverage, including
individual or group health insurance, prepaid plans such as HMOs,
or government plans such as Medicare. The BRFSS survey is
conducted by telephone and is designed to produce state-level
estimates [15].
2.3. Analysis
We estimated the percentage of women living in the catchment
area with at least one Pap test during a calendar year differently for
insured and uninsured women as outlined below and in Fig. 1.
(A) Screening percentage estimation among insured women with
1 Pap smear during a calendar year:
First we estimated the number of insured women living in the
catchment area by age group by multiplying US Census
population estimates by estimates of the percentage of the
population insured from the American Community Survey (ACS).
ACS data offered only one overall estimate of the percentage
insured by year for so we used that same estimate for all age
groups. Then, we estimated the percentage of all insured women
whose claims were captured by QCorp by dividing the number of
enrollees reported by QCorp for calendar year by our census- and
Table 1
Data sources used to estimate cervical cancer screening percentages.
Data source Data obtained
Census data Population counts
American Community Survey Estimates of percentage of insured and uninsured women
Claims administrative data De-duplicated counts of women enrolled in a health plan
De-duplicated counts of insured women who had a Pap
Oregon’s behavioral risk factor
Surveillance system (BRFSS)
Pap percentage in insured and uninsured women
Relative frequency of Pap smear among uninsured and insured women
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Fig. 1. Estimating annual Pap screening percentage by insurance status.
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ACS-based estimate of the number of insured women in the
catchment area. Then we estimated the total number of Pap
smears done among all insured women in the catchment area by
dividing the number of women living in the catchment area with
at least one QCorp Pap smear claim during a calendar year by our
estimate of the percentage of all insurance claims captured by
QCorp. This latter step adjusted counts of Pap tests reported by
QCorp for incomplete claims capture. Finally, we estimated
screening percentages among insured women in the catchment
area by dividing the adjusted count of insured women with at
least one Pap test during the calendar year by overall estimates of
the insured population.
We report cervical cancer screening percentages by calendar
year overall, and within age groups among women aged 18–20, 21–
29, and 30–39 years, based on current screening guidelines that do
not recommend regular screening for women aged <21 years and
include extended screening intervals of three years for women
aged >29 years if they have had 3 consecutive negative high risk
HPV test results.
(B) Screening percentage estimation among uninsured women
with 1 Pap smear during calendar year:
To estimate the percentage of uninsured women who had a Pap
during each calendar year, we multiplied the claims-based
estimates of the percentage of insured women with 1 Pap test
by an estimate of relative Pap test frequency among uninsured and
insured women. We estimated relative Pap test frequency by age-
group using aggregated Oregon BRFSS survey data from 2010, 2012,
2013 and 2014 by dividing the percentage of uninsured women
who reported a Pap test within the previous 12 months by the
percentage of insured women who reported a Pap test within the
Table 2
Estimates of insured population, numbers of Pap smears among insured women, and percentage of women with Pap smears by year by insured, uninsured and overall, by age
group, 28-zipcode area, Portland, Oregon 2008–2012.
Year Estimated number of
insured women
Estimated number of Pap
smears, insured women
Estimated insured women
(%) with 1 Pap smear
Estimated uninsured women
(%) with 1 Pap smeara
Overall estimated women
(%) with 1 Pap smearb
Credible
range (%)
Age 18–20
2008 9076 1439 15.9 18.2 16.3 (11.3–18.4)
2009 9043 1892 20.9 24.1 21.5 (16.7–26.4)
2010 8496 1067 12.6 14.4 12.9 (9.7–16.3)
2011 8629 734 8.5 9.8 8.7 (6.7–10.8)
2012 8699 460 5.3 3.7 5.4 (4.3–6.6)
Age 21–29
2008 41685 14270 34.2 21.3 31.9 (29.8–34.0)
2009 42239 15691 37.1 23.1 34.6 (32.4–37.0)
2010 40315 14064 34.9 21.7 32.2 (30.0–34.5)
2011 41578 14136 34.0 21.1 31.6 (29.5–33.8)
2012 42672 12975 30.4 20.1 28.5 (26.6–30.4)
Age 30–39
2008 45507 17043 37.5 21.6 34.6 (32.5–37.3)
2009 46149 17913 38.8 22.4 35.9 (33.5–38.4)
2010 44122 15670 35.5 20.5 32.4 (30.1–34.8)
2011 45587 15168 33.3 19.2 30.6 (28.6–32.8)
2012 46810 14133 30.2 15.4 28.0 (26.2–30.0)
Age 18–39
2008 96268 32267 33.5 20.8 31.2 (29.3–33.1)
2009 97431 34913 35.8 22.3 33.4 (31.4–35.5)
2010 92933 30049 32.3 20.1 29.8 (27.9–31.8)
2011 95794 29146 30.4 18.9 28.3 (26.5–30.1)
2012 98181 26718 27.2 15.5 25.5 (23.9–27.1)
a Obtained by multiplying claims-based estimate of percentage of insured women by Behavioral Risk Factor Surveillance-based estimate of relative Pap test frequency
among insured and uninsured women.
b Weighted average of estimates among insured and uninsured women.
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previous 12 months, appropriately weighted for BRFSS survey
design.
(C) Overall estimate:
We estimated the overall percentage with a Pap during a
calendar year as a weighted average of the estimates of
percentages of insured and uninsured women that received a
Pap smear during calendar year [16].
2.4. Credible intervals
To create ranges around annual percentage calculations, we
used Monte Carlo simulations to reflect the combined uncertainty
in input parameters, including percentage of population insured
from American Community Survey, total Population from US
Census, number of claims and number of insured women whose
claims could have been captured by QCorp (“enrolled”), and
relative prevalence ratio from Behavioral Risk Factor Surveillance
Survey. For those estimates drawn from sources with published
methods for which variance was provided or could be calculated,
we assigned normal distributions. For estimates of claims and
enrolled women provided by QCorp we assigned a more
conservative triangular distribution and allowed the estimates
to range by 5% in either direction. We set the variation in QCorp
counts after discussion with QCorp analysts. Using the Crystal Ball
software application, we created credible intervals around Pap
smear percentage estimates by conducting 100,000 repeated
calculations for each point estimate.
3. Results
(A) Screening percentage estimation among insured women with
1 Pap smear during a calendar year: From 27.2% to 33.5% of
insured women aged 18–39 years were screened annually from
2008 to 2012 (Table 2).
(B) Screening percentage estimation among uninsured women
with 1 Pap smear during calendar year: The relative past-year
Pap test frequency smear among insured and uninsured
women was 1.6.
(C) Overall estimate: Among women aged 18–39 years, the
estimated percentage screened increased from 31.2% in
2008 to 33.4% in 2009; and then declined to 25.5% in 2012
(Table 2 and Fig. 2). Compared to 2009, credible intervals did not
overlap in 2011 or 2012. From 2008 to 2009, screening increased
inwomenaged18–20years (16.3%to21.5%), then fell eachyear to
5.4% in 2012. Compared with 2009, credible intervals did not
overlap in 2010, 2011 or 2012. Among women aged 20–29 years
screening increased from31.9% in2008to34.6% in2009andthen
decreased slightly in subsequent years to 28.5% in 2012.
However, compared to 2009 credible intervals overlapped
during 2010, 2011, but not in 2012. Among women aged 30–
39 years screening increased slightly from 2008 to 2009 (34.6–
35.9%), then fell in each year during 2009 (35.9%) through 2012
(28.0%). Compared to 2009, credible intervals did not overlap in
2011 or 2012. Between groups (Fig. 2), credible intervals did not
overlap in any year for women aged 18–20 years compared to
women in either of the two older age groups. Between the two
older age groups, credible intervals overlapped in every year.
4. Discussion
As far as we know, these are the first published estimates of the
percentage of women with Pap screening in a general population
derived from actual Pap test counts based on administrative
claims. We found that screening increased for all age groups from
2008 to 2009 and declined for all groups thereafter. Declines were
more dramatic for women aged 18–20 years in whom the
percentage screened decreased from almost 21.5% to 5.4%. We
also observed significant but less dramatic declines in Pap smear
screening percentages among women aged 21–29 and 30–39 years.
These results likely reflect new screening guidelines introduced in
2009 and modified in 2012. In 2009, screening guidelines
recommended that screening begin at age 21 years, with routine
screenings every 2 years until age 29 years [17]. Decreasing Pap
smear screening percentages in our study area likely represent
adoption of these guidelines. Newer guidelines released in
2012 recommend that screening begin at age 21 years, with
routine screenings every 3 years [18]. We expect to see the same or
even lower screening percentages following addition of new
screening guidelines.
Similar percentages of women screened and declines in
screening during the same period were recently reported by
Fig. 2. Percentage of women who reported cervical cancer screening in the past 12 months by age group, Oregon 2008–2012.
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Cuzick et al. based on data from New Mexico’s unique Pap smear
registry in 2013 [4]. The decrease was greatest in the 15–20 years
age-group from 22.4% in 2008 to 8.7% in 2011. Reductions in all
other age groups during this period were smaller, ranging between
3% and 6% for absolute reductions.
Our annual average estimate of the percentage of women aged
18–39 years screened from 2008 through 2012 was 29.6%. This
estimate of the percentage of women screened differs from
estimates obtained from BRFSS. From 2008 to 2012, BRFSS
estimated that an average of 61.5% of insured women reported a
Pap smear within the previous 12 months. The BRFSS survey relies
on self-report. Over-estimation due to self-report bias probably
explains the substantially higher survey-based screening percen-
tages compared to claims data.
In 2004, Insinga et al. reported 31.2% of girls and women
enrolled in Kaiser Permanente Northwest Health Plan in Oregon
and aged 10 years received any Pap smear screening during 1998
[10]. Most Kaiser patients reside in the same metropolitan area
that we studied. Though our age groups do not precisely coincide,
this is somewhat higher than the 25.5% of all women—insured and
uninsured—aged 18–39 that we estimate receive a Pap smear
during 2012. The difference is likely explained by the fact that
Insinga et al. studied a fully insured, health maintenance
organization population at a time when major professional
organizations recommended initiating Pap smears at the time of
onset of sexual activity with annual Pap smears thereafter.
Before 2012, cervical cancer screening guidelines by American
Cancer Society (ACS), United States Preventive Services Task Force
(USPSTF), and the American College of Obstetricians and Gynecol-
ogist (ACOG), differed on age to start and frequency of screening
[18]. In 2012, however, all three organizations recommended that
screening begin at 21 years of age regardless of onset of sexual
activity, should be performed every 3 years for women 21–29 years
of age, and combined with HPV testing for longer screening
intervals for women 30–65 years. Recommendations for screening
women aged 65 years continue to differ slightly among these
organizations. As a result of the new guidelines, frequent use of
liquid-based cytology and HPV testing technologies, the National
Cancer Institute has predicted that fewer Pap tests will be
performed.
HPV vaccination is expected to reduce the incidence of cervical
disease and consequently, cervical cancer [19]. Measured inci-
dence of CIN2+ depends on the actual occurrence of disease and on
the percentage of the population that gets screened. Therefore, in
light of the changing recommendations, and the current use of HPV
vaccine, accurate estimates of women who receive a Pap smear
during a given time period are key to measuring the impact of the
HPV vaccine. Future estimates of cervical dysplasia incidence
should adjust for screening to avoid wrongly attributing changes in
measured incidence related to screening utilization to changes in
underlying disease incidence.
5. Limitations
Our source of claims data extended across multiple insurers
and the majority of insured women. This allowed us to avoid
double counting women who had multiple Pap tests during a
calendar year, even if claims were made within different health
systems. However, though the source captures a majority of
claims, not all insurers participate and not all claims are captured.
We attempted to adjust for incomplete claims capture by
assuming that the percentage of insured women screened by
non-participating insurers was the same as the percentage
screened by participating insurers. If non-reporting health plans
had systematically higher or lower overall percentages of women
screened during a calendar year than reporting plans, our
estimate would be affected. We are not aware of any reason to
believe that either of these scenarios might be true. We also used
a wide range around our estimates of claims and enrolled women
with a conservative triangular distribution to account for greater
uncertainty of these estimates in generation of Monte-Carlo
simulation-based credible intervals.
We derived our estimate of the percentage of uninsured women
screened directly from our estimate of the percentage of insured
women screened by multiplying by an estimate of the “relative
frequency” of Pap smears among uninsured to insured women
screened from survey data. This approach propagates any error
inherent in the direct approach to estimation of percentage of
insured women screened. This approach introduces further error
only to the extent that accuracy of self-report varies by insured
status. Assuming, as we did, that self-report bias is equivalent in
insured and uninsured women, our approach eliminates self-
report bias.
American Community Survey, our source of data about the
percentage of the population that was insured did not offer the
ability to estimate age-group specific percentages. To the extent
that we over- or underestimated in-group proportions of insured
women our estimates might be flawed. Underestimating insured
proportion would bias estimates downward while overestimating
would bias them upwards.
6. Conclusion
This study introduces a novel method for population-level
estimates of cervical cancer screening percentages. Traditionally,
these estimates have been obtained by self-reported data, or from
administrative data from a single managed care provider. Our
methods estimate Pap smear screening percentages in both
insured and uninsured women to derive population-level screen-
ing percentages.
Overall, the cervical cancer screening rate for women aged 18–
39 years and residing within the Portland, Oregon catchment area
increased from 31.2% in 2008 to 33.4% in 2009. Thereafter, the
screening percentage decreased to 25.5% in 2012. We expect HPV
vaccination to reduce the incidence of high-grade cervical
dysplasia (and ultimately, cervical cancer). However, because of
recent changes in screening recommendations, ascertainment of
incident cases of CIN2+ is likely to decrease as well, rendering
crude (unadjusted for screening) estimates of high-grade dysplasia
incidence difficult to interpret. This method allows evaluating the
impact of vaccination of CIN2+ trends that are not confounded by
changes in screening.
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Appendix A.
Codes to identify cervical cancer screening
CPT code
88141 Cytopathology, cervical or vaginal requiring interpretation by
physician
88142 Cytopathology, cervical or vaginal, manual screening under physician
supervision
88143 Cytopathology, cervical or vaginal, manual screening and re-screening
under physician supervision
88147 Cytopathology smears, cervical or vaginal, screening by automated
system under physician supervision
88148 Cytopathology smears, cervical or vaginal, screening by automated
system with manual re-screening under physician supervision
88150 Cytopathology, slides, cervical or vaginal, manual screening under
physician supervision
88152 Cytopathology, slides, cervical or vaginal, manual screening and
computer-assisted re-screening under physician supervision
88153 Cytopathology, slides, cervical or vaginal, with manual screening and
re-screening under physician supervision
88154 Cytopathology, slides, cervical or vaginal, manual screening, computer-
assisted re-screening using cell selection, under physician supervision
88164 Cytopathology, slides, cervical or vaginal (Bethesda System), manual
screening under physician supervision
88165 Cytopathology, slides, cervical or vaginal (Bethesda System), manual
screening and re-screening under physician supervision
88166 Cytopathology, slides, cervical or vaginal (Bethesda System), manual
screening and computer-assisted re-screening under physician
supervision
88167 Cytopathology, slides, cervical or vaginal (Bethesda System), manual
screening & computer-assisted re-screening using cell selection under
physician supervision
88174 Cytopathology, cervical or vaginal, collected in preservative fluid,
automated thin layer preparation, screening by automated system,
under physician supervision
88175 Cytopathology, cervical or vaginal, collected in preservative fluid,
automated thin layer preparation, with screening by automated system
and manual re-screening or review, under physician supervision
HCPCS code
G0123 Screening cytopathology, cervical or vaginal, collected in preservative
fluid, automated thin layer preparation, screening by cytotech under
physician supervision
G0124 Screening cytopathology, cervical or vaginal, collected in preservative
fluid, automated thin layer preparation, requiring interpretation by
physician
G0141 Screening cytopathology smears, cervical or vaginal, performed by
automated system, with manual re-screening, requiring interpretation
by physician
G0143 Screening cytopathology, cervical or vaginal, collected in preservative
fluid, automated thin layer preparation, with manual screening and re-
screening by cytotechnologist under physician supervision
G0144 Screening cytopathology, cervical or vaginal, collected in preservative
fluid, automated thin layer preparation, with screening by automated
system under physician supervision
G0145 Screening cytopathology, cervical or vaginal, collected in preservative
fluid, automated thin layer preparation, with screening by automated
system and manual re-screening under physician supervision
G0147 Screening cytopathology smears, cervical or vaginal, performed by
automated system under physician supervision
G0148 Screening cytopathology smears, cervical or vaginal, performed by
automated system with manual re-screening
P3000 Screening papanicolaou smear, cervical or vaginal, up to three smears,
by technician under physician supervision
P3001 Screening papanicolaou smear, cervical or vaginal, up to three smears,
requiring interpretation by physician
Q0091 Screening papanicolaou smear, obtaining, preparing and conveyance of
cervical or vaginal smear to laboratory
ICD-9 code
91.46 Microscopic examination of specimen from female genital tract; cell
block and Pap smear
UB revenue code
923 Pap smear
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